Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from HOYA ( (JP:7741) ).
HOYA Corporation has postponed the planned spin-off of its Japanese endoscope business, which is to be transferred via a simplified absorption-type company split to its wholly owned subsidiary PENTAX Medical Corporation. The effective date, initially scheduled for May 1, 2026, has been pushed back to August 1, 2026, following a resolution by management.
The delay stems from administrative procedures in various countries taking longer than the company had anticipated, reflecting the regulatory complexity of restructuring a cross-border medical device business. HOYA states that the revised timing is not expected to affect its consolidated financial results, suggesting limited immediate impact on earnings while the structural reorganization of its endoscope operations proceeds as planned.
The most recent analyst rating on (JP:7741) stock is a Buy with a Yen30000.00 price target. To see the full list of analyst forecasts on HOYA stock, see the JP:7741 Stock Forecast page.
More about HOYA
HOYA Corporation is a Japan-based technology company best known for its optical products, including eyeglass lenses, medical endoscopes, and other healthcare and information technology-related optical components. The group operates globally with a strong presence in medical imaging and diagnostics, where its endoscope business, under the Pentax Medical brand, targets hospitals and clinics seeking advanced minimally invasive diagnostic solutions.
Average Trading Volume: 1,076,848
Technical Sentiment Signal: Buy
Current Market Cap: Yen9595.6B
Learn more about 7741 stock on TipRanks’ Stock Analysis page.